Regenxbio Inc. (RGNX): Llc Fmr , 10% owner other of Regenxbio Inc. sold 18,900 shares on Apr 15, 2016. The Insider selling transaction was reported by the company on Apr 19, 2016 to the Securities and Exchange Commission. The shares were sold at $11.75 per share for a total value of $222,132.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 15, 2016, Llc Fmr (10% owner other) sold 27,036 shares at $11.48 per share price.
Institutional Investors own 56.32% of Regenxbio Inc shares.
REGENXBIO Inc. formerly ReGenX Biosciences LLC is a biotechnology company focused on the development commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companys AAV gene delivery platform (its NAV technology platform) consists of exclusive rights to over 100 AAV vectors including AAV7 AAV8 AAV9 and AAVrh10 (NAV Vectors). The Company focuses on the lives of patients suffering from diseases with unmet medical needs by developing and commercializing gene therapy products administered directly into the body or in vivo based on its NAV technology platform. Its NAV technology platform is applied in the development of over 20 product candidates for a range of diseases including five product candidates and approximately 20 partnered product candidates developed by its NAV technology licensees. The Companys products candidates include RGX-501 RGX-111 RGX-121 RGX-314 and RGX-321.